SUPERNUS PHARMACEUTICALS, INC. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Supernus Pharmaceuticals and Indivior announced a tax-free stock merger in which Supernus shareholders receive 1.5401 Indivior shares per share, resulting in 43.5% Supernus and 56.5% Indivior ownership post-close. Prior to closing, Indivior will distribute $1 billion in aggregate dividends to pre-closing shareholders. The combined company, retaining the Supernus name, targets Q4 2026 close, projects $2.2B in combined LTM revenues (as of 6/30/26), expects $125M+ annual cost synergies, and maintains 0.99x pro forma net leverage after $650M debt for the dividend.
Why this rating
Transformational M&A substantially increases scale (~$1.7B company becomes ~$2.2B), material synergies ($125M ≈ 5.8% of revenue), but execution risk remains significant. Relative to company size, material but not existential; stock-for-stock mitigates immediate dilution concerns.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.